Viking Therapeutics, Inc.(VKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VKTX Viking Therapeutics, Inc.

盘后交易 09-02 17:57:46 EDT

33.50

-0.17

-0.50%

盘后33.49

-0.01-0.04%

17:37 EDT

最高34.75	最低32.77	成交量157.25万
今开33.67	昨收33.67	日振幅5.88%
总市值39.08亿	流通市值36.85亿	总股本1.17亿
成交额5,262万	换手率1.43%	流通股本1.10亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"VKTX","market":"US","secType":"STK","nameCN":"Viking Therapeutics, Inc.","latestPrice":33.5,"timestamp":1788379200000,"preClose":33.67,"halted":0,"volume":1572514,"hourTrading":{"tag":"盘后","latestPrice":33.4875,"preClose":33.5,"latestTime":"17:37 EDT","volume":23496,"amount":787113.18048,"timestamp":1788385029491,"change":-0.0125,"changeRate":-0.000373,"amplitude":0.030448},"delay":0,"changeRate":-0.005049005049005099,"floatShares":110000000,"shares":116652937,"eps":-4.66765,"marketStatus":"盘后交易","change":-0.17,"latestTime":"09-02 17:57:46 EDT","open":33.67,"high":34.75,"low":32.7708,"amount":52616730.438668,"amplitude":0.058782,"askPrice":34,"askSize":1000,"bidPrice":32.8,"bidSize":50,"shortable":3,"etf":0,"ttmEps":-4.66765,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1788393600000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1430280000000,"exchange":"NASDAQ","adjPreClose":33.67,"preHourTrading":{"tag":"盘前","latestPrice":33.73,"preClose":33.67,"latestTime":"09:29 EDT","volume":4981,"amount":167526.23699299997,"timestamp":1788355799999,"change":0.06,"changeRate":0.001782,"amplitude":0.019602},"postHourTrading":{"tag":"盘后","latestPrice":33.4875,"preClose":33.5,"latestTime":"17:37 EDT","volume":23496,"amount":787113.18048,"timestamp":1788385029491,"change":-0.0125,"changeRate":-0.000373,"amplitude":0.030448},"volumeRatio":0.855207,"impliedVol":1.0711,"impliedVolPercentile":0.9524},"requestUrl":"/m/hq/s/VKTX","defaultTab":"news","newsList":[{"id":"1131883109","title":"异动解读｜Viking Therapeutics盘中上涨8.68%，新型减肥药VK3019启动一期临床试验提振市场情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1131883109","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131883109?lang=zh_cn&edition=full","pubTime":"2026-07-08 03:35","pubTimestamp":1783452928,"startTime":"0","endTime":"0","summary":"7月8日，Viking Therapeutics盘中上涨8.68%，报42.07美元/股，成交额1.33亿美元。消息面上，公司近期宣布已启动在研减肥药VK3019的一期单剂量递增临床试验，此前该药已获得美国FDA的新药临床试验申请批准。VK3019为双重淀粉样蛋白和降钙素受体激动剂，该试验为随机、双盲、安慰剂对照研究，旨在评估BMI≥30健康成人中皮下注射VK3019的安全性、耐受性及疗效。多条管线持续推进叠加分析师平均目标价约94.62美元，支撑市场对公司减肥药布局的乐观预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164828121","title":"Viking Therapeutics启动VK3019一期临床试验，评估新型淀粉样蛋白受体激动剂在健康成人中的效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1164828121","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164828121?lang=zh_cn&edition=full","pubTime":"2026-06-24 19:06","pubTimestamp":1782299197,"startTime":"0","endTime":"0","summary":"Viking Therapeutics宣布，已启动一项一期临床研究，旨在评估其新型淀粉样蛋白受体激动剂VK3019在健康成年受试者中的表现。该研究标志着VK3019这一在研药物正式进入人体试验阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VKTX","BK4585","BK4599","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125765038","title":"Viking Therapeutics在2026年欧洲肥胖症大会上公布VK2735口服给药二期VENTURE试验13周数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1125765038","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125765038?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:06","pubTimestamp":1778583978,"startTime":"0","endTime":"0","summary":"Viking Therapeutics公司在2026年欧洲肥胖症大会上，公布了其候选药物VK2735口服给药二期VENTURE试验为期13周的研究数据。\n该试验旨在评估VK2735在肥胖或超重成人中的疗效与安全性。公布的数据涵盖了药物对患者体重、腰围及其他相关代谢指标的影响。\n研究结果显示，经过13周的治疗，接受VK2735治疗的患者在体重减轻方面取得了具有统计学意义的改善。此外，药物在试验中展现出了可接受的安全性特征。\n这些积极数据进一步支持了VK2735作为一种潜在的口服肥胖治疗方案的持续开发。公司计划基于这些结果，推进该药物的后续临床研究。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX","BK4588","BK4585","BK4139","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517619311","title":"Viking Therapeutics, Inc.盘中异动 早盘大幅上涨5.01%报29.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517619311","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517619311?lang=zh_cn&edition=full","pubTime":"2025-03-06 23:09","pubTimestamp":1741273775,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日23时09分，Viking Therapeutics, Inc.股票出现波动，股价大幅上涨5.01%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.44%。其相关个股中，Aeon Biopharma, Inc.、Plus Therapeutics, Inc.、Tonix Pharmaceuticals Holding Corp.涨幅较大，Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Aditxt, Inc.较为活跃，换手率分别为1475.89%、720.61%、73.18%，振幅较大的相关个股有Moolec Science Sa C/Wts 、Aeon Biopharma, Inc.、Coeptis Therapeutics Holdings Inc C/Wts 28/10/2027 ，振幅分别为44.44%、42.11%、39.20%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306230935989ebc93&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306230935989ebc93&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4139","VKTX","LENZ","BK4585","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516263769","title":"Viking Therapeutics, Inc.盘中异动 早盘大幅下跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516263769","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516263769?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:52","pubTimestamp":1741013569,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时52分，Viking Therapeutics, Inc.股票出现异动，股价急速下挫5.02%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.06%。其相关个股中，Bioxcel Therapeutics, Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、木薯科学涨幅较大，Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为687.62%、115.08%、86.65%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Pliant Therapeutics, Inc.，振幅分别为163.15%、70.53%、40.78%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303225249989a15a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303225249989a15a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","VKTX","BK4139","BK4588","BK4599","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514038900","title":"Viking Therapeutics, Inc.盘中异动 股价大涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514038900","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514038900?lang=zh_cn&edition=full","pubTime":"2025-02-27 23:23","pubTimestamp":1740669804,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日23时23分，Viking Therapeutics, Inc.股票出现异动，股价大幅上涨5.03%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.14%。其相关个股中，Quoin Pharmaceuticals Ltd、Alpha Tau Medical Ltd C/Wts 、Editas Medicine, Inc.涨幅较大，Quoin Pharmaceuticals Ltd、Aeon Biopharma, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为884.66%、177.60%、104.83%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Pds Biotechnology Corporation、Quoin Pharmaceuticals Ltd，振幅分别为74.16%、43.51%、34.80%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227232324abdf7c41&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227232324abdf7c41&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VKTX","BK4588","BK4599","LENZ","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514017433","title":"现金9亿美金\"子弹充足\"！Viking能否复制礼来神话？","url":"https://stock-news.laohu8.com/highlight/detail?id=2514017433","media":"美港股观察社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514017433?lang=zh_cn&edition=full","pubTime":"2025-02-25 18:00","pubTimestamp":1740477639,"startTime":"0","endTime":"0","summary":"VK2735口服开发进展在2024年4月，Viking Therapeutics报告了口服VK2735治疗肥胖受试者4周的数据，但剂量最高仅为40毫克。2024年11月，Viking Therapeutics在ObesityWeek上展示了这些额外的结果，并指出接受100毫克VK2735治疗的9名患者中仅出现轻度恶心。财务概况截至2024年底，Viking Therapeutics拥有9.03亿美元的现金、现金等价物和短期投资。公司报告该季度净亏损为3540万美元。Viking Therapeutics尚未提交10-K年报。然而，2025年2月的公司文件提供的财务摘要显示，流通股为1.116亿股，使Viking Therapeutics的市值达到38亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226015322abdcae97&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226015322abdcae97&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BK4W5L77.USD","LU2491050071.SGD","LU1868837136.USD","LU0109391861.USD","IE0002141913.USD","SG9999014880.SGD","LU2361044865.SGD","LU1988902786.USD","LU1291159041.SGD","SGXZ99366536.SGD","LU0640476718.USD","LU2237443549.SGD","LU1267930730.SGD","LU0820561818.USD","LU1974910355.USD","LU0114720955.EUR","LLY","LU1868836914.USD","LU2237443895.HKD","LU2264538146.SGD","LU1720051017.SGD","LU1548497426.USD","LU1551013342.USD","LU2491050154.USD","LU1280957306.USD","LU0203201768.USD","LU2106854487.HKD","VKTX","LU1057294990.SGD","LU2491049909.HKD","LU1868837300.USD","LU0417517546.SGD","IE00BFTCPJ56.SGD","BK4588","LU1069344957.HKD","LU2324357040.USD","SG9999015945.SGD","LU0106261372.USD","SG9999015952.SGD","BK4534","LU2461242641.AUD","SGXZ51526630.SGD","LU1983299246.USD","IE00BK4W5M84.HKD","LU2602419157.SGD","LU2237443978.SGD","LU0256863811.USD","LU0058720904.USD","SG9999015978.USD","IE00B4R5TH58.HKD","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2513727908","title":"Viking Therapeutics, Inc.盘中异动 早盘急速下跌5.20%报32.30美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513727908","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513727908?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:32","pubTimestamp":1740407523,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时32分，Viking Therapeutics, Inc.股票出现异动，股价快速下挫5.20%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.09%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。公司临床方案管线包括VK2809、VK5211、VK0214产品。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223203abdb0df3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223203abdb0df3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4599","VKTX","BK4588","BK4585","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513218261","title":"Viking Therapeutics, Inc.盘中异动 股价大涨5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513218261","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513218261?lang=zh_cn&edition=full","pubTime":"2025-02-22 01:23","pubTimestamp":1740158624,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日01时23分，Viking Therapeutics, Inc.股票出现波动，股价快速拉升5.22%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.39%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。公司临床方案管线包括VK2809、VK5211、VK0214产品。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222012345988e0421&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222012345988e0421&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","VKTX","BK4588","BK4599","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512918489","title":"Viking Therapeutics, Inc.盘中异动 快速拉升5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512918489","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512918489?lang=zh_cn&edition=full","pubTime":"2025-02-19 23:47","pubTimestamp":1739980024,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日23时47分，Viking Therapeutics, Inc.股票出现波动，股价大幅上涨5.02%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.60%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。公司临床方案管线包括VK2809、VK5211、VK0214产品。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219234705abd50efe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219234705abd50efe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","BK4588","BK4139","VKTX","LENZ","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511543812","title":"Viking Therapeutics(VKTX.US)获Scotiabank首次覆盖，给予跑赢大盘评级, 目标价102.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2511543812","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511543812?lang=zh_cn&edition=full","pubTime":"2025-02-13 19:11","pubTimestamp":1739445090,"startTime":"0","endTime":"0","summary":"Viking Therapeutics(VKTX.US)获Scotiabank首次覆盖，给予跑赢大盘评级, 目标价102.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/13191148145872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","VKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510086164","title":"Viking Therapeutics, Inc.盘中异动 快速下跌5.07%报30.91美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510086164","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510086164?lang=zh_cn&edition=full","pubTime":"2025-02-10 23:44","pubTimestamp":1739202254,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日23时44分，Viking Therapeutics, Inc.股票出现波动，股价快速下跌5.07%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.08%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210234414a240b24d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210234414a240b24d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","VKTX","BK4599","LENZ","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510837051","title":"Viking Therapeutics, Inc.2024财年实现净利润-1.10亿美元，同比减少28.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510837051","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510837051?lang=zh_cn&edition=full","pubTime":"2025-02-09 00:00","pubTimestamp":1739030455,"startTime":"0","endTime":"0","summary":"2月9日，Viking Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-1.10亿美元，同比减少28.06%；其中营业收入为0.00美元，每股基本收益为-1.01美元。从资产负债表来看，Viking Therapeutics, Inc.总负债28.04百万美元，其中短期债务489000.00美元，资产负债比为0.33，流动比率为0.34。机构评级：截至2025年2月9日，当前有16家机构对Viking Therapeutics, Inc.目标价做出预测，其中目标均价为99.12美元，其中最低目标价为38.00美元，最高目标价为164.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250209000100abc7642a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250209000100abc7642a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","VKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509708900","title":"Viking Therapeutics(VKTX.US)获花旗首次覆盖，给予中性评级, 目标价38.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509708900","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509708900?lang=zh_cn&edition=full","pubTime":"2025-02-08 07:23","pubTimestamp":1738970611,"startTime":"0","endTime":"0","summary":"Viking Therapeutics(VKTX.US)获花旗首次覆盖，给予中性评级, 目标价38.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/08072348032046.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["VKTX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509708875","title":"Maxim Group：维持Viking Therapeutics(VKTX.US)评级，由买入调整至买入评级, 目标价由120.00美元调整至70.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509708875","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509708875?lang=zh_cn&edition=full","pubTime":"2025-02-08 07:11","pubTimestamp":1738969876,"startTime":"0","endTime":"0","summary":"Maxim Group：维持Viking Therapeutics(VKTX.US)评级，由买入调整至买入评级, 目标价由120.00美元调整至70.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/08071148032042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","VKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140953316","title":"异动解读 | 维京治疗公司盘中大跌9.91%,肥胖症药物试验进展增量不足令投资者失望","url":"https://stock-news.laohu8.com/highlight/detail?id=1140953316","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140953316?lang=zh_cn&edition=full","pubTime":"2025-02-06 23:04","pubTimestamp":1738854246,"startTime":"0","endTime":"0","summary":"维京治疗公司(Viking Therapeutics,代码VKTX)今日盘中股价大跌9.91%,引发市场广泛关注。\n公司公布财报数据令投资者失望。每股亏损0.32美元,高于预期0.28美元,净亏损比去年同期扩大28%至3540万美元。研发费用大幅上升是亏损扩大的主因,包括临床试验费用及候选药物制造成本增加。\n更令投资者担忧的是,公司实验性肥胖症药物VK2735试验最新进展只是增量,未达市场预期。在此背景下,投资者通过抛售来表达对公司前景的担忧,导致股价暴跌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509272737","title":"Viking Therapeutics, Inc.盘中异动 早盘快速下挫10.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509272737","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509272737?lang=zh_cn&edition=full","pubTime":"2025-02-06 22:31","pubTimestamp":1738852274,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日22时31分，Viking Therapeutics, Inc.股票出现异动，股价大幅下挫10.45%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.12%。其相关个股中，Lipella Pharmaceuticals Inc.、Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Transcode Therapeutics, Inc.涨幅较大，Lipella Pharmaceuticals Inc.、Transcode Therapeutics, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为3685.57%、328.87%、113.29%，振幅较大的相关个股有Lipella Pharmaceuticals Inc.、Moleculin Biotech, Inc.、Invivyd, Inc.，振幅分别为19.38%、10.08%、9.48%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206223114abc4d425&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206223114abc4d425&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","BK4139","BK4588","LENZ","VKTX","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509220857","title":"Piper Sandler：维持Viking Therapeutics(VKTX.US)评级，由增持调整至增持评级, 目标价由74.00美元调整至71.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509220857","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509220857?lang=zh_cn&edition=full","pubTime":"2025-02-06 20:22","pubTimestamp":1738844560,"startTime":"0","endTime":"0","summary":"Piper Sandler：维持Viking Therapeutics(VKTX.US)评级，由增持调整至增持评级, 目标价由74.00美元调整至71.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/06202247996064.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","VKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103387478","title":"异动解读 | 维京治疗公司大跌9.16%，业绩疲软令投资者失望","url":"https://stock-news.laohu8.com/highlight/detail?id=1103387478","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103387478?lang=zh_cn&edition=full","pubTime":"2025-02-06 17:05","pubTimestamp":1738832701,"startTime":"0","endTime":"0","summary":"维京治疗公司(VKTX)在盘前大跌9.16%,引起了市场关注。\n\n公司公布的2024年第四季度财报数据令人失望。财报显示,维京治疗公司当季每股亏损高达0.32美元,大幅逊于分析师普遍预期的每股亏损0.28美元。与去年同期相比,公司净亏损更是扩大了28%,达到3540万美元。\n\n亏损超预期主要原因是公司研究与开发费用不断攀升,包括候选药物的制造成本、员工薪酬福利以及临床试验费用。虽然公司CEO表示在多个临床试验中取得进展,但业绩未如预期,加深了投资者对公司前景的担忧,引发资金抛售,推动股价暴跌。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124353019","title":"异动解读 | 维京医疗公司公布亏损扩大 股价夜盘暴跌10.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=1124353019","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124353019?lang=zh_cn&edition=full","pubTime":"2025-02-06 09:02","pubTimestamp":1738803763,"startTime":"0","endTime":"0","summary":"根据公司2024年第四季度财报,维京医疗公司(Viking Therapeutics)当季每股亏损0.32美元,远高于分析师平均预期的每股亏损0.28美元。与去年同期相比,公司亏损扩大了28%,引发投资者担忧。\n\n加之公司临床研究费用和相关开支继续上升,研发投入不断加大,导致当季净亏损高达3540万美元。尽管公司CEO表示取得了多项重大临床进展,但业绩未及预期,引发市场质疑公司前景。\n\n消息公布后,维京医疗公司在夜盘大幅下挫,收盘时跌幅超过10%,引发市场广泛关注。一度因超乎预期的亏损和高昂研发开支而遭资金抛售。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VKTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vikingtherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0146},{"period":"1month","weight":0.0608},{"period":"3month","weight":0.148},{"period":"6month","weight":0.0685},{"period":"1year","weight":0.2447},{"period":"ytd","weight":-0.0429}],"compareEarnings":[{"period":"1week","weight":-0.0054},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.01},{"period":"6month","weight":0.1181},{"period":"1year","weight":0.181},{"period":"ytd","weight":0.1171}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Viking Therapeutics, Inc.于2012年9月24号在特拉华州成立。该公司是一个临床阶段的生物制药公司，致力于开发新的，第一类或最好的新陈代谢和内分泌失调类疗法。该公司拥有全球独家权利基于许可的配体小分子组合在五个候选药物在临床试验或临床前研究。公司的主导临床程序是VK0612，它是进入2b期临床试验为2型全球最大的健康挑战之一的治疗糖尿病疾病口服药物，它在同药物中排列第一。公司的第二临床程序vk5211，可把口服的候选药物送入第二阶段临床试验治疗一种复杂的疾病特点的不受控制的肌肉质量下降癌症恶病。VK5211是一种非甾体选择性雄激素受体调节剂，或SARM。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":-0.006749},{"month":2,"riseRate":0.545455,"avgChangeRate":0.220725},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.034739},{"month":4,"riseRate":0.454545,"avgChangeRate":0.013541},{"month":5,"riseRate":0.333333,"avgChangeRate":0.076833},{"month":6,"riseRate":0.416667,"avgChangeRate":-0.004304},{"month":7,"riseRate":0.5,"avgChangeRate":-0.000671},{"month":8,"riseRate":0.5,"avgChangeRate":0.013958},{"month":9,"riseRate":0.333333,"avgChangeRate":0.051723},{"month":10,"riseRate":0.363636,"avgChangeRate":0.052351},{"month":11,"riseRate":0.454545,"avgChangeRate":-0.018186},{"month":12,"riseRate":0.545455,"avgChangeRate":0.143438}],"exchange":"NASDAQ","name":"Viking Therapeutics, Inc.","nameEN":"Viking Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Viking Therapeutics, Inc.(VKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Viking Therapeutics, Inc.(VKTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Viking Therapeutics, Inc.,VKTX,Viking Therapeutics, Inc.股票,Viking Therapeutics, Inc.股票老虎,Viking Therapeutics, Inc.股票老虎国际,Viking Therapeutics, Inc.行情,Viking Therapeutics, Inc.股票行情,Viking Therapeutics, Inc.股价,Viking Therapeutics, Inc.股市,Viking Therapeutics, Inc.股票价格,Viking Therapeutics, Inc.股票交易,Viking Therapeutics, Inc.股票购买,Viking Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Viking Therapeutics, Inc.(VKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Viking Therapeutics, Inc.(VKTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}